$HALB Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
https://www.accesswire.com/725430/halberd-sig...aceuticals
* Accelerated Sales of HALB's Patented Products through newly formed "The Hamden Group".
JACKSON CENTER, PA / ACCESSWIRE / November 14, 2022 / Halberd Corporation (OTC-PINK:HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the sales and marketing of pharmaceutical products. Darren Hamans is a Consultant for Business Development of the Halberd Corporation. Darren Hamans created the Hamden Group for sales and distribution of Halberd's medicinal therapeutics. Brad and Todd Croden are partners with Daren Hamans in Hamden. Through this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product. Details of the agreement will be forthcoming.
The partners in Hamden include Brad and Todd Croden, Brad is the son of Peter Croden. Peter Croden was the past President of various divisions of Upjohn Corporation. Brad and Todd Croden have combined experience of almost four decades in the pharmaceutical industry. Darren Hamans, the CEO of the Hamden Group, stated, "Hamden was created to greatly increase revenues for the Halberd Corporation."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added," This is truly a major milestone for Halberd, as this group has the potential for greatly accelerating sales of the HALB Naltrexone product covered by our intellectual patent license. Naltrexone has been shown to have a great deal of benefit for patients with MS, fibromyalgia, migraine headaches, chemical and alcohol addiction, and chronic pain syndromes. The potential of sales of this product is huge. The Hamden Group will also help in developing greater sales for our proprietary Vita-Shield-Max™ Nutraceutical Product and assist HALB in pursuing big pharma partners through their extensive industry contacts."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
https://www.accesswire.com/725430/halberd-sig...aceuticals
* Accelerated Sales of HALB's Patented Products through newly formed "The Hamden Group".
JACKSON CENTER, PA / ACCESSWIRE / November 14, 2022 / Halberd Corporation (OTC-PINK:HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the sales and marketing of pharmaceutical products. Darren Hamans is a Consultant for Business Development of the Halberd Corporation. Darren Hamans created the Hamden Group for sales and distribution of Halberd's medicinal therapeutics. Brad and Todd Croden are partners with Daren Hamans in Hamden. Through this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product. Details of the agreement will be forthcoming.
The partners in Hamden include Brad and Todd Croden, Brad is the son of Peter Croden. Peter Croden was the past President of various divisions of Upjohn Corporation. Brad and Todd Croden have combined experience of almost four decades in the pharmaceutical industry. Darren Hamans, the CEO of the Hamden Group, stated, "Hamden was created to greatly increase revenues for the Halberd Corporation."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added," This is truly a major milestone for Halberd, as this group has the potential for greatly accelerating sales of the HALB Naltrexone product covered by our intellectual patent license. Naltrexone has been shown to have a great deal of benefit for patients with MS, fibromyalgia, migraine headaches, chemical and alcohol addiction, and chronic pain syndromes. The potential of sales of this product is huge. The Hamden Group will also help in developing greater sales for our proprietary Vita-Shield-Max™ Nutraceutical Product and assist HALB in pursuing big pharma partners through their extensive industry contacts."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
